Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 6Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Lung Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Stomach Neoplasms 2Neoplasm Metastasis 2Melanoma 2Head and Neck Neoplasms 2Disease 2Colonic Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vasculitis 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoking Cessation 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Osteomyelitis 1Nose Neoplasms 1Myelodysplastic Syndromes 1Multiple Pulmonary Nodules 1

Interventions

Rituximab 134Cyclophosphamide 100Vincristine 53fludarabine phosphate 50Prednisone 50Doxorubicin 49Etoposide 47Peripheral Blood Stem Cell Transplantation 38Mycophenolic Acid 37Whole-Body Irradiation 35Tacrolimus 29Busulfan 27Lenalidomide 26Filgrastim 26Cyclosporine 26Melphalan 24Methotrexate 21Antilymphocyte Serum 21Gemcitabine 18ibritumomab tiuxetan 17Granulocyte Colony-Stimulating Factor 17Cytarabine 17Carmustine 16Radiotherapy 15fludarabine 14Carboplatin 14Bendamustine Hydrochloride 14pembrolizumab 13ibrutinib 12Sirolimus 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Large B-Cell, Diffuse × Positron-Emission Tomography × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡